SIONHealthcare · BiotechnologySION Stock Forecast: Sionna Therapeutics, Inc. Price Predictions for 2026-2027
The 11 Wall Street analysts covering Sionna Therapeutics, Inc. hold a median 12-month price target of $54 — +9.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 42 of 100 as at 1 Aug 2026 — in the lower half.
SION stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Sionna Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (80): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Growth (18): Sales and profits are flat, shrinking, or growing more slowly than they were.
The rank is the raw material. Whether the rules would actually own Sionna Therapeutics, Inc. — and when they’d sell — is the membership.
SION stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on SION, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +9.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 26 May 2026 | Citizens | Reiterates | Market Outperform | $63 |
| 20 May 2026 | Freedom Broker | Downgrade | Hold | $38 |
| 18 May 2026 | Stifel | Maintains | Buy | — |
| 13 May 2026 | BTIG | Reiterates | Buy | — |
| 5 May 2026 | Wedbush | Initiates | Outperform | — |
| 28 Apr 2026 | Jones Trading | Maintains | Buy | — |
| 27 Apr 2026 | BTIG | Reiterates | Buy | — |
| 3 Mar 2026 | Guggenheim | Maintains | Buy | — |
| 2 Mar 2026 | BTIG | Reiterates | Buy | — |
| 24 Feb 2026 | Citizens | Initiates | Market Outperform | — |
| 14 Jan 2026 | BTIG | Reiterates | Buy | — |
| 7 Jan 2026 | BTIG | Maintains | Buy | — |
| 23 Dec 2025 | LifeSci Capital | Initiates | Outperform | — |
| 1 Dec 2025 | RBC Capital | Downgrade | Underperform | — |
| 19 Nov 2025 | BTIG | Initiates | Buy | — |
| 17 Oct 2025 | Freedom Broker | Initiates | Buy | — |
| 17 Oct 2025 | Freedom Capital Markets | Initiates | Buy | $38 |
| 8 Sept 2025 | Jones Trading | Initiates | Buy | — |
| 3 Sept 2025 | Raymond James | Initiates | Strong Buy | — |
| 3 Sept 2025 | RBC Capital | Initiates | Sector Perform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
SION analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Sionna Therapeutics, Inc. (SION) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −26.1×
- Price / sales
- —
- Price / book
- 7.7×
- EV / EBITDA
- −19.5×
Cheaper than 97% of US stocks
Cheaper than 13% of US stocks
Cheaper than 89% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −26.7%
- Return on assets
- −18.3%
- Dividend yield
- —
Higher than 28% of US stocks
Higher than 21% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
SION vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SION appears on the weeks it earns a place.
Frequently asked questions about SION stock
What is the SION stock price forecast for 2026-2027?
The 11 Wall Street analysts covering Sionna Therapeutics, Inc. have a median 12-month price target of $54, with estimates ranging from $23 to $63. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is SION stock a buy right now?
Of the 11 analysts covering Sionna Therapeutics, Inc., 9 rate it a Buy, 1 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Sionna Therapeutics, Inc. 42 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank SION?
As at 1 Aug 2026, Sionna Therapeutics, Inc. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (80 of 100).
Will SION stock go up?
No one can know that. What the data says: the median 12-month target from 11 analysts implies +9.6% from the last close, and Ticker Nerd's factor model ranks Sionna Therapeutics, Inc. 42 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the SION stock forecast for 2030?
No analyst covering Sionna Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SION are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $23 to $63 over the next 12 months.
How has SION stock performed over the past year?
Sionna Therapeutics, Inc. returned +191.1% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Sionna Therapeutics, Inc. do?
Sionna Therapeutics Inc. is a biotechnology company focused on developing innovative therapies to address cystic fibrosis, a genetic disorder that impacts the respiratory and digestive systems.
About Sionna Therapeutics, Inc.
Sionna Therapeutics Inc. is a biotechnology company focused on developing innovative therapies to address cystic fibrosis, a genetic disorder that impacts the respiratory and digestive systems. The company's primary goal is to advance research and therapeutic approaches that restore the balance of chloride ions, pivotal for treating this life-altering condition. Sionna Therapeutics is dedicated to exploring new treatment avenues by leveraging cutting-edge scientific methods and novel chemical entities. Concentrating primarily on the health and pharmaceuticals sector, the company is part of a niche industry aimed at improving health outcomes for patients with chronic and rare diseases. Sionna Therapeutics plays a crucial role in the healthcare market by targeting unmet medical needs, potentially transforming the lives of those affected by cystic fibrosis. With a commitment to innovation and patient care, the company strives to make significant contributions to the field of genetic medicine.
CEO Mr. Michael Cloonan M.B.A. · 59 employees · United States · https://www.sionnatx.com